Investors & Media

What’s new.

Press releases

Press releases.

June 23rd 2025

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases

May 26th 2025

Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

May 15th 2025

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

more

Investor updates

Investor updates.

April 23rd 2025

Investor Update - April 2025

November 26th 2024

Investor Update - November 2024

February 21st 2024

Investor Update - February 2024

more

Analyst reports

Analyst reports.

June 23rd 2025

Baird - Updated Phase 1 Safety/Efficacy HV Data for IMP761 (LAG-3) for Autoimmune; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)

For a copy of this research report please contact your Baird advisor

June 23rd 2025

Canaccord Genuity - IMP761 PhI shows good safety and T cell suppression; BUY, A$0.98 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

May 16th 2025

Maxim - Positive Response Data from INSIGHT-003 in 1L NSCLC; Bodes Well for Ongoing P3 Pivotal TACTI-004 Study - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

more